Northwest Biotherapeutics Inc
NWBOOTCCIK 1072379HealthcareFiscal year ends Dec 31
Reports and events: 313 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-10-3016:10 ET | 8-K | 1.01 Entry into a material agreement; 2.03 New direct financial obligation | 0001104659-26-120669 |
| 2026-08-1416:17 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0001104659-26-097188 |
| 2026-07-3117:17 ET | 8-K | 1.01 Entry into a material agreement; 2.03 New direct financial obligation | 0001104659-26-089293 |
| 2026-07-2019:48 ET | 8-K | 7.01 Regulation FD disclosure | 0001104659-26-084743 |
| 2026-05-1516:34 ET | 10-Q | Quarterly reportPeriod 2026-03-31 | 0001104659-26-062661 |
| 2026-04-1516:16 ET | 10-K | Annual reportPeriod 2025-12-31 | 0001104659-26-043806 |
| 2026-04-0712:30 ET | 8-K | 2.01 Completion of an acquisition or disposition | 0001104659-26-040260 |
| 2026-01-1517:06 ET | 8-K | 8.01 Other events | 0001104659-26-004146 |
| 2026-01-0217:14 ET | 8-K | 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001104659-26-000243 |
| 2025-11-2816:43 ET | DEF 14A | Proxy statementPeriod 2025-12-29 | 0001104659-25-116966 |
| 2025-11-2016:26 ET | 8-K | 1.01 Entry into a material agreement; 2.03 New direct financial obligation | 0001104659-25-114627 |
| 2025-11-1416:44 ET | 10-Q | Quarterly reportPeriod 2025-09-30 | 0001104659-25-112676 |
| 2025-10-3112:29 ET | 8-K | 1.01 Entry into a material agreement; 2.03 New direct financial obligation | 0001104659-25-104812 |
| 2025-10-3016:40 ET | 8-K | 1.01 Entry into a material agreement | 0001104659-25-104427 |
| 2025-10-2412:28 ET | 8-K | 8.01 Other events | 0001104659-25-102049 |
| 2025-10-1414:22 ET | 8-K | 8.01 Other events | 0001104659-25-099196 |
| 2025-08-1417:00 ET | 10-Q | Quarterly reportPeriod 2025-06-30 | 0001410578-25-001825 |
| 2025-05-1516:23 ET | 10-Q | Quarterly reportPeriod 2025-03-31 | 0001410578-25-001333 |
| 2025-03-3117:23 ET | 10-K | Annual reportPeriod 2024-12-31 | 0001410578-25-000598 |
| 2024-12-2616:29 ET | 8-K | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0001104659-24-131723 |
| 2024-11-1216:10 ET | 10-Q | Quarterly reportPeriod 2024-09-30 | 0001410578-24-001879 |
| 2024-11-0117:24 ET | 8-K | 1.01 Entry into a material agreement; 2.03 New direct financial obligation | 0001104659-24-113553 |
| 2024-08-0917:06 ET | 10-Q | Quarterly reportPeriod 2024-06-30 | 0001410578-24-001278 |
| 2024-08-0210:42 ET | 8-K | 7.01 Regulation FD disclosure | 0001104659-24-085198 |
| 2024-07-0314:44 ET | 8-K | 5.07 Shareholder vote results | 0001104659-24-077718 |
| 2024-06-0417:11 ET | 8-K | 1.01 Entry into a material agreement | 0001104659-24-068314 |
| 2024-06-0317:22 ET | DEF 14A | Proxy statementPeriod 2024-06-29 | 0001104659-24-067885 |
| 2024-05-1017:04 ET | 10-Q | Quarterly reportPeriod 2024-03-31 | 0001410578-24-000741 |
| 2024-05-0216:39 ET | 8-K | 1.01 Entry into a material agreement; 2.03 New direct financial obligation | 0001104659-24-056424 |
| 2024-04-2917:03 ET | 10-K/A | Annual report, amendedPeriod 2023-12-31 | 0001104659-24-054153 |
| 2024-03-2216:30 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001104659-24-037901 |
| 2024-03-1416:30 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001104659-24-034527 |
| 2024-03-0517:14 ET | 10-K | Annual reportPeriod 2023-12-31 | 0001410578-24-000133 |
| 2023-11-1617:11 ET | 8-K | 1.01 Entry into a material agreement; 2.03 New direct financial obligation | 0001104659-23-119165 |
| 2023-11-0916:30 ET | 10-Q | Quarterly reportPeriod 2023-09-30 | 0001410578-23-002304 |
| 2023-08-0916:36 ET | 10-Q | Quarterly reportPeriod 2023-06-30 | 0001410578-23-001633 |
| 2023-05-1016:33 ET | 10-Q | Quarterly reportPeriod 2023-03-31 | 0001410578-23-000976 |
| 2023-03-0816:56 ET | 8-K | 1.01 Entry into a material agreement; 2.03 New direct financial obligation | 0001104659-23-030141 |
| 2023-02-2816:27 ET | 10-K | Annual reportPeriod 2022-12-31 | 0001410578-23-000185 |
| 2023-01-1316:34 ET | 8-K | 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001104659-23-003846 |
| 2023-01-0616:41 ET | 8-K | 5.07 Shareholder vote results | 0001104659-23-001886 |
| 2022-12-0507:00 ET | DEF 14A | Proxy statementPeriod 2022-12-30 | 0001104659-22-124360 |
| 2022-11-0916:27 ET | 10-Q | Quarterly reportPeriod 2022-09-30 | 0001410578-22-003073 |
| 2022-08-0916:12 ET | 10-Q | Quarterly reportPeriod 2022-06-30 | 0001410578-22-002177 |
| 2022-07-2616:47 ET | 8-K | 3.03 Change to security holders’ rights; 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001104659-22-082813 |
| 2022-06-3017:08 ET | 10-K/A | Annual report, amendedPeriod 2021-12-31 | 0001104659-22-076361 |
| 2022-05-1017:58 ET | 10-Q | Quarterly reportPeriod 2022-03-31 | 0001410578-22-001218 |
| 2022-05-0217:03 ET | 10-K/A | Annual report, amendedPeriod 2021-12-31 | 0001104659-22-054757 |
| 2022-03-0112:48 ET | 10-K | Annual reportPeriod 2021-12-31 | 0001410578-22-000244 |
| 2021-11-2916:29 ET | 8-K | 1.01 Entry into a material agreement; 2.03 New direct financial obligation | 0001104659-21-144456 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 30, 2026, 16:18 ET. Listed shows no prices and gives no investment advice.